Figure 6From: Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patientsImpact of the absence (blue line) and presence (green line) of oligoclonal reconstitution on EFS, showing a superior EFS in patients with oligoclonal reconstitution.Back to article page